Heat Biologics, Inc. – AMEX:HTBX
Founder-led company
Heat Biologics stock price today
$2.38
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Heat Biologics stock price monthly change
-2.46%
month
Heat Biologics stock price quarterly change
-5.18%
quarter
Heat Biologics stock price yearly change
-61.05%
year
Heat Biologics key metrics
Market Cap | 61.07M |
Enterprise value | 48.39M |
P/E | -2.06 |
EV/Sales | 58.62 |
EV/EBITDA | -1.36 |
Price/Sales | 73.78 |
Price/Book | 0.57 |
PEG ratio | -0.15 |
EPS | -1.42 |
Revenue | 825.51K |
EBITDA | -35.49M |
Income | -35.89M |
Revenue Q/Q | -60.56% |
Revenue Y/Y | -68.06% |
Profit margin | -4359.59% |
Oper. margin | -4270.57% |
Gross margin | 0% |
EBIT margin | -4270.57% |
EBITDA margin | -4299.59% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHeat Biologics stock price history
Heat Biologics stock forecast
Heat Biologics financial statements
| Jun 2021 | 459.49K | -6.54M | -1424% |
|---|---|---|---|
| Sep 2021 | 501.56K | -7.43M | -1481.9% |
| Dec 2021 | -347.96K | -13.60M | 3911.03% |
| Mar 2022 | 212.41K | -8.31M | -3912.33% |
| 2021-08-11 | -0.28 | -0.26 |
|---|---|---|
| 2021-11-10 | -0.29 | -0.3 |
| 2022-03-14 | -0.32 | -0.54 |
| Jun 2021 | 138789519 | 8.31M | 5.99% |
|---|---|---|---|
| Sep 2021 | 132655225 | 8.78M | 6.63% |
| Dec 2021 | 120961233 | 8.92M | 7.38% |
| Mar 2022 | 114266522 | 9.56M | 8.37% |
| Jun 2021 | -6.15M | -3.40M | -30.17K |
|---|---|---|---|
| Sep 2021 | -15.73M | 2.12M | -61.16K |
| Dec 2021 | 0 | 0 | 0 |
| Mar 2022 | -10.21M | 16.79M | -55.19K |
Heat Biologics alternative data
| Aug 2023 | 49 |
|---|---|
| Sep 2023 | 49 |
| Oct 2023 | 49 |
| Nov 2023 | 49 |
| Dec 2023 | 49 |
| Jan 2024 | 49 |
| Feb 2024 | 49 |
| Mar 2024 | 49 |
| Apr 2024 | 49 |
| May 2024 | 49 |
| Jun 2024 | 49 |
| Jul 2024 | 49 |
Heat Biologics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2020 | 0 | 103304 |
| May 2021 | 0 | 35000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | PRENDERGAST JOHN K A director | Common Stock | 35,000 | $5.87 | $205,310 | ||
Sale | SMITH EDWARD B III director | Common Stock | 103,304 | $1.03 | $106,403 | ||
Option | OSTRANDER WILLIAM L. officer: CFO/Corp.. | Common Stock | 15,625 | $0.52 | $8,125 | ||
Option | OSTRANDER WILLIAM L. officer: CFO/Corp.. | Employee Stock Option (right to buy) | 15,625 | $0.52 | $8,125 | ||
Purchase | KHARITONOV MICHAEL director | Common Stock | 900,000 | $0.75 | $675,000 | ||
Purchase | PRICE MELISSA officer: VP of Product Developm.. | Common Stock | 692 | $4.3 | $2,976 | ||
Purchase | WOLF JEFFREY ALAN director, officer.. | Common Stock | 2,500 | $4.1 | $10,250 | ||
Purchase | BELSKY PAUL director | Common Stock | 2,500 | $4.11 | $10,275 | ||
Purchase | WOLF JEFFREY ALAN director, officer.. | Common Stock | 51 | N/A | N/A | ||
Purchase | BELSKY PAUL director | Common Stock | 51 | N/A | N/A |
| Patent |
|---|
Application Filling date: 3 Dec 2018 Issue date: 25 Nov 2021 |
Application Filling date: 1 Oct 2019 Issue date: 11 Nov 2021 |
Application Filling date: 2 Mar 2021 Issue date: 16 Sep 2021 |
Application Filling date: 27 Nov 2018 Issue date: 10 Jun 2021 |
Application Filling date: 24 Jul 2020 Issue date: 7 Jan 2021 |
Grant Filling date: 25 Jun 2018 Issue date: 22 Sep 2020 |
Grant Filling date: 25 Jun 2018 Issue date: 1 Sep 2020 |
Application COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS Filling date: 8 Apr 2020 Issue date: 20 Aug 2020 |
Application COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS Filling date: 9 Mar 2020 Issue date: 6 Aug 2020 |
Grant Utility: Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins Filling date: 29 Jun 2018 Issue date: 26 May 2020 |
-
What's the price of Heat Biologics stock today?
One share of Heat Biologics stock can currently be purchased for approximately $2.38.
-
When is Heat Biologics's next earnings date?
Unfortunately, Heat Biologics's (HTBX) next earnings date is currently unknown.
-
Does Heat Biologics pay dividends?
No, Heat Biologics does not pay dividends.
-
How much money does Heat Biologics make?
Heat Biologics has a market capitalization of 61.07M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 28.33% to 2.11M US dollars. Heat Biologics made a loss 35.4M US dollars in net income (profit) last year or -$0.54 on an earnings per share basis.
-
What is Heat Biologics's stock symbol?
Heat Biologics, Inc. is traded on the AMEX under the ticker symbol "HTBX".
-
What is Heat Biologics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Heat Biologics?
Shares of Heat Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Heat Biologics's key executives?
Heat Biologics's management team includes the following people:
- Mr. Jeffrey Alan Wolf J.D. Founder, Chairman, Chief Executive Officer & Pres(age: 62, pay: $1,160,000)
- Mr. William L. Ostrander Chief Financial Officer & Sec.(age: 57, pay: $271,920)
-
Is Heat Biologics founder-led company?
Yes, Heat Biologics is a company led by its founder Mr. Jeffrey Alan Wolf J.D..
-
How many employees does Heat Biologics have?
As Jul 2024, Heat Biologics employs 49 workers.
-
When Heat Biologics went public?
Heat Biologics, Inc. is publicly traded company for more then 12 years since IPO on 24 Jul 2013.
-
What is Heat Biologics's official website?
The official website for Heat Biologics is heatbio.com.
-
Where are Heat Biologics's headquarters?
Heat Biologics is headquartered at 627 DAVIS DRIVE, SUITE 400, Morrisville, NORTH CAROLINA.
-
How can i contact Heat Biologics?
Heat Biologics's mailing address is 627 DAVIS DRIVE, SUITE 400, Morrisville, NORTH CAROLINA and company can be reached via phone at +1 919 240 7133.
Heat Biologics company profile:
Heat Biologics, Inc.
heatbio.comExchange:
AMEX
Full time employees:
49
Industry:
Biotechnology
Sector:
Healthcare
Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
627 DAVIS DRIVE, SUITE 400
Morrisville, NORTH CAROLINA 27560
Morrisville, NORTH CAROLINA 27560
CIK: 0001476963
ISIN: US42237K3005
CUSIP: 42237K300
